Alzheimer’s disease (AD) can be divided into five distinct subtypes based on protein expression levels measured in the cerebrospinal fluid (CSF). The subtypes were associated with different genetic risk factors and are likely to benefit from different treatment approaches.
Many clinicians, drug developers and the general public still “think of Alzheimer’s as a single disease entity, and that suggests that every patient needs to have the same medication,” Betty Tijms told BioWorld. Read More
Pulmonary arterial hypertension (PAH), characterized by vasoconstriction and pulmonary vascular remodeling, has a 10% annual mortality rate among patients due to right heart failure. There are genetic variants known to impact the risk of PAH, but susceptibility from epigenetic changes is poorly understood. Read More
Olema Pharmaceuticals Inc. has advanced its program targeting KAT6, an epigenetic target dysregulated in breast and other cancers, with the selection of a development candidate, OP-3136. The orally bioavailable, potent KAT6A/B-selective inhibitor has been developed by Olema in collaboration with Aurigene Oncology Ltd. Read More
Beam Therapeutics Inc. has offered a progress update on its genetic disease franchise. BEAM-302, the company’s priority genetic disease program, is a potential treatment for α1-antitrypsin deficiency (AATD). Read More
The use of α-glucosidase inhibitors reduces postprandial glucose levels and increases insulin sensitivity, and is thus ideal for combination with insulin therapy. Read More
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are one of the major advances for non-small-cell lung cancer (NSCLC) management in recent years. Read More
Researchers from Florey Neuroscience Institutes, Monash University and Olivia Newton-John Cancer Research Institute have identified fluorine-radiolabeled compounds acting as tyrosine-protein kinase Mer (MERTK) inhibitors and also as positron emission tomography (PET) imaging agents reported to be useful for the diagnosis and treatment of multiple sclerosis (MS). Read More
Kriya Therapeutics Inc. has offered an update on its pipeline of gene therapies for indications in ophthalmology, metabolic disease and neurology. Read More
Researchers from Yangzhou University presented the discovery and preclinical characterization of LysZX4-NCA, a new endolysin therapeutic being developed for the treatment of multidrug-resistant highly virulent Klebsiella pneumoniae (MDR-hvKP) infections. Read More
Researchers at Jiangsu Hengrui Medicine Co. Ltd., Shanghai Fourth People’s Hospital Affiliated Tongji University and Shanghai Senhui Pharmaceutical Co. Ltd. have divulged cyclopentyl adenosine derivatives reported to be useful for the treatment of chronic pain. Read More
Keiferx LLC has expanded its exclusive licensing agreement with Georgetown University to advance the development of novel tyrosine kinase inhibitor (TKI) chemical entities for the treatment of multiple disease indications. Read More
Patients with celiac disease have gluten-specific CD4+ T cells that recognize gluten via disease-associated human leukocyte antigen (HLA) molecules, specifically HLA-DQ2.5, leading to immune activation and enteropathy. Read More
Monte Rosa Therapeutics Inc. has described molecular glue degraders comprising cereblon ligands and a casein kinase 1 Isoform α (CK1α) targeting moiety acting as CK1α degradation inducers reported to be useful for the treatment of cancer. Read More
